Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Targeted Oncology
Published in: Targeted Oncology 4/2018

01-08-2018 | Original Research Article

Preparation of Folic Acid-Targeted Temperature-Sensitive Magnetoliposomes and their Antitumor Effects In Vitro and In Vivo

Authors: Xihui Wang, Rui Yang, Chunyan Yuan, Yanli An, Qiusha Tang, Daozhen Chen

Published in: Targeted Oncology | Issue 4/2018

Login to get access

Abstract

Background

Ovarian cancer is a common gynecologic malignancy with poor prognosis, requiring innovative new therapeutic strategies. Temperature-controlled drug delivery to cancer cells represents a novel, promising, targeted treatment approach.

Objective

We prepared folate receptor-targeted thermosensitive liposomes wrapped with the HSP90 inhibitor 17-AAG and superparamagnetic material (17-AAG/MTSLs-FA), and tested the efficacy of these targeted magnetoliposomes in vitro and in vivo.

Methods

Magnetic thermosensitive liposomes wrapped with 17-AAG were coprecipitated with Fe3O4 magnetic nanoparticles and prepared by a rotary evaporation method. Experiments were conducted with SKOV3 human ovarian cancer cells and MCF7 human breast carcinoma cells to evaluate the anti-tumor effects.

Results

17-AAG/MTSLs-FA prepared in this study met the basic requirements for therapeutic application. The preparation method is relatively simple and the raw materials are readily available. The product exhibited strong magnetism, high encapsulation efficiencies, and satisfactory performance. The liposomes combined with hyperthermia significantly inhibited the proliferation of SKOV3 cells and induced apoptosis. Experiments using a mouse subcutaneous model as well as an ascites tumor xenograft model indicated that 17-AAG/MTSLs-FA was stable in vivo and effectively targeted tumor tissues expressing the folate receptor.

Conclusions

Folic acid-conjugated 17-AAG magnetic thermosensitive liposomes in combination with an alternating magnetic field for heating can achieve a synergistic anti-tumor effect of chemotherapy and heat treatment, potentially offering a new method for ovarian cancer treatment.
Literature
1.
2.
3.
Pelicci PG, Dalton P, Orecchia R. Heating cancer stem cells to reduce tumor relapse. Breast Cancer Res. 2011;13(3):1–2.CrossRef
4.
5.
Jordan A, Scholz R, Wust P, Fähling H, Felix R. Magnetic fluid hyperthermia (MFH): Cancer treatment with AC magnetic field induced excitation of biocompatible superparamagnetic nanoparticles. J Magn Magn Mater. 1999;201(1–3):413–9.CrossRef
6.
Hu R, Ma S, Ke X, Jiang H, Wei D, Wang W. Effect of interleukin-2 treatment combined with magnetic fluid hyperthermia on Lewis lung cancer-bearing mice. Biomed Rep. 2016;4(1):59–62.CrossRefPubMed
7.
Li XH, Rong PF, Jin HK, Wang W, Tang JT. Magnetic fluid hyperthermia induced by radiofrequency capacitive field for the treatment of transplanted subcutaneous tumors in rats. Exp Ther Med. 2012;3(2):279.CrossRefPubMed
8.
Duncan RF. Inhibition of Hsp90 function delays and impairs recovery from heat shock. FEBS J. 2005;272(20):5244–56.CrossRefPubMed
9.
Giubellino A, Sourbier C, Lee MJ, Scroggins B, Bullova P, Landau M, et al. Targeting heat shock protein 90 for the treatment of malignant pheochromocytoma. PLoS ONE. 2013;8(2):e56083.CrossRefPubMedPubMedCentral
10.
Katragadda U, Fan W, Wang Y, Teng Q, Tan C. Combined delivery of paclitaxel and tanespimycin via micellar nanocarriers: pharmacokinetics, efficacy and metabolomic analysis. PLoS ONE. 2013;8(3):e58619.CrossRefPubMedPubMedCentral
11.
Kneidl B, Peller M, Winter G, Lindner LH, Hossann M. Thermosensitive liposomal drug delivery systems: state of the art review. Int J Nanomed. 2014;2014(1):4387–98.
12.
Lokerse WJM, Bolkestein M, Hagen TLMT, Jong MD, Eggermont AMM, Grüll H, et al. Investigation of particle accumulation, chemosensitivity and thermosensitivity for effective solid tumor therapy using thermosensitive liposomes and hyperthermia. Theranostics. 2016;6(10):1717–31.CrossRefPubMedPubMedCentral
13.
Hossann M, Syunyaeva Z, Schmidt R, Zengerle A, Eibl H, Issels RD, et al. Proteins and cholesterol lipid vesicles are mediators of drug release from thermosensitive liposomes. J Control Release. 2012;162(2):400–6.CrossRefPubMed
14.
Moussa M, Goldberg SN, Kumar G, Sawant RR, Levchenko T, Torchilin VP, et al. Nanodrug-enhanced radiofrequency tumor ablation: effect of micellar or liposomal carrier on drug delivery and treatment efficacy. PLoS ONE. 2014;9(8):e102727.CrossRefPubMedPubMedCentral
15.
Dicheva BM, Hagen TLMT, Schipper D, Seynhaeve ALB, Rhoon GCV, Eggermont AMM, et al. Targeted and heat-triggered doxorubicin delivery to tumors by dual targeted cationic thermosensitive liposomes. J Control Release. 2014;195:37-48.CrossRefPubMed
16.
Zhan C, Li C, Wei X, Lu W, Lu W. Toxins and derivatives in molecular pharmaceutics: drug delivery and targeted therapy. Adv Drug Deliv Rev. 2015;90:101–18.CrossRefPubMed
17.
Reddy JA, Allagadda VM, Leamon CP. Targeting therapeutic and imaging agents to folate receptor positive tumors. Curr Pharm Biotechnol. 2005;6(2):131-50.
18.
Yang R, An YL, Miao FQ, Li MF, Liu PD, Tang QS. Preparation of folic acid-conjugated, doxorubicin-loaded, magnetic bovine serum albumin nanospheres and their antitumor effects in vitro and in vivo. Int J Nanomed. 2014;2014(1):4231–43.CrossRef
19.
Yang R, An LY, Miao QF, Li FM, Han Y, Wang HX, et al. Effective elimination of liver cancer stem-like cells by CD90 antibody targeted thermosensitive magnetoliposomes. Oncotarget. 2016;7(24):35894–916.PubMedPubMedCentral
20.
Devarajan E, Huang S. STAT3 as a central regulator of tumor metastases. Curr Mol Med. 2009;9(5):626–33.
21.
Prabhu RH, Patravale VB, Joshi MD. Polymeric nanoparticles for targeted treatment in oncology: current insights. Int J Nanomed. 2015;10(1):1001–18.
22.
Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev. 2001;53(2):283–318.PubMed
23.
Chen C, Ke J, Zhou XE, Yi W, Brunzelle JS, Li J, et al. Structural basis for molecular recognition of folic acid by folate receptors. Nature. 2013;500(7463):486.CrossRefPubMedPubMedCentral
24.
Zhang Y, Guo L, Roeske RW, Antony AC, Jayaram HN. Pteroyl-γ-glutamate-cysteine synthesis and its application in folate receptor-mediated cancer cell targeting using folate-tethered liposomes. Anal Biochem. 2004;332(1):168–77.CrossRefPubMed
25.
Gabizon A, Shmeeda H, Horowitz AT, Zalipsky S. Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv Drug Deliv Rev. 2004;56(8):1177–92.CrossRefPubMed
26.
Bañobrelópez M, Teijeiro A, Rivas J. Magnetic nanoparticle-based hyperthermia for cancer treatment. Rep Pract Oncol Radiother. 2013;18(6):397–400.CrossRef
27.
Li R, Zheng K, Yuan C, Chen Z, Huang M. Be active or not: the relative contribution of active and passive tumor targeting of nanomaterials. Nano. 2017;1(4):346.
28.
Deshantri AK, Kooijmans SA, Kuijpers SA, Coimbra M, Hoeppener A, Storm G, et al. Liposomal prednisolone inhibits tumor growth in a spontaneous mouse mammary carcinoma model. J Control Release. 2016;243:243–9.CrossRefPubMed
29.
Creixell M, Bohórquez AC, Torres-Lugo M, Rinaldi C. EGFR-targeted magnetic nanoparticle heaters kill cancer cells without a perceptible temperature rise. ACS Nano. 2011;5(9):7124–9.CrossRefPubMed
30.
Huang HC, Yang Y, Nanda A, Koria P, Rege K. Synergistic administration of photothermal therapy and chemotherapy to cancer cells using polypeptide-based degradable plasmonic matrices. Nanomedicine. 2011;6(3):459–73.CrossRefPubMed
31.
Xia M, Huang R, Sakamuru S, Alcorta D, Cho MH, Lee DH, et al. Identification of repurposed small molecule drugs for chordoma therapy. Cancer Biol Ther. 2013;14(7):638–47.CrossRefPubMedPubMedCentral
32.
Lee RJ, Low PS. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim Biophys Acta. 1995;1233(2):134–44.CrossRefPubMed
33.
Hong J, Sun Z, Li Y, Guo Y, Liao Y, Liu M, et al. Folate-modified Annonaceous acetogenins nanosuspensions and their improved antitumor efficacy. Int J Nanomed. 2017;12:5053–67.CrossRef
34.
De BE, Rosing H, Michalakis J, Romanos J, Relakis K, Theodoropoulos PA, et al. Intraperitoneal chemotherapy with taxanes for ovarian cancer with peritoneal dissemination. Eur J Surg Oncol. 2006;32(6):666–70.CrossRef
35.
Elit L, Oliver TK, Covens A, Kwon J, Fung MF, Hirte HW, et al. Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses. Cancer. 2010;109(4):692–702.CrossRef
36.
Jaaback K, Johnson N, Lawrie TA. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev. 2006;129(1):CD005340.
Metadata
Title
Preparation of Folic Acid-Targeted Temperature-Sensitive Magnetoliposomes and their Antitumor Effects In Vitro and In Vivo
Authors
Xihui Wang
Rui Yang
Chunyan Yuan
Yanli An
Qiusha Tang
Daozhen Chen
Publication date
01-08-2018
Publisher
Springer International Publishing
Published in
Targeted Oncology / Issue 4/2018
Print ISSN: 1776-2596
Electronic ISSN: 1776-260X
DOI
https://doi.org/10.1007/s11523-018-0577-y

Other articles of this Issue 4/2018

Targeted Oncology 4/2018 Go to the issue

Review Article

The Role of Autophagy in the Resistance to BRAF Inhibition in BRAF-Mutated Melanoma

Therapy in Practice

Coronary Toxicities of Anti-PD-1 and Anti-PD-L1 Immunotherapies: a Case Report and Review of the Literature and International Registries

Adis Drug Evaluation

Inotuzumab Ozogamicin: A Review in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia

Short Communication

Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors

Review Article

Growing Role of Regorafenib in the Treatment of Patients with Sarcoma

Review Article

MicroRNAs as Mediators of Resistance Mechanisms to Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumours
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits